Cytoimmune Biologics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1M

  • Investors
  • 2

Cytoimmune Biologics General Information

Description

Developer of an integrated ecosystem of biologic and cell therapy technologies and capabilities designed to commercialise a wide range of regenerative medicines. The company's platform offers a focused approach to differentiated technologies and research & development efforts, including a clinical cell manufacturing facility tailored to support the advancement and commercialisation of innovative NK cell therapies, enabling partners such as researchers, medical professionals, and biotech companies to access cell therapy and enhance the well-being of cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 845 Meridian Street
  • Duarte, CA 91010
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 845 Meridian Street
  • Duarte, CA 91010
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytoimmune Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 01-Jan-2023 $1M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 06-Aug-2021 Completed Pre-Clinical Trials
To view Cytoimmune Biologics’s complete valuation and funding history, request access »

Cytoimmune Biologics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Cytoimmune Biologics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Cytoimmune Biologics Patents

Cytoimmune Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023034758-A1 Methods and compositions for cell expansion Inactive 30-Aug-2021
WO-2023278335-A1 Methods and compositions for cell expansion Inactive 28-Jun-2021
WO-2022240808-A1 Methodsand compositions for efficiently expanding cord blood nk cells Inactive 11-May-2021
JP-2023540997-A Methods and compositions for infecting, activating, and expanding immune cells Pending 08-Sep-2020
AU-2021341944-A1 Methods and compositions of infecting, activating, and expanding immune cells Inactive 08-Sep-2020 A61K40/15
To view Cytoimmune Biologics’s complete patent history, request access »

Cytoimmune Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cytoimmune Biologics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Myeloma Investment Fund Not-For-Profit Venture Capital Minority
Sofinnova Partners Venture Capital Minority
To view Cytoimmune Biologics’s complete investors history, request access »

Cytoimmune Biologics Investments (1)

Cytoimmune Biologics’s most recent deal was a PIPE with Hemostemix for . The deal was made on 04-Feb-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Hemostemix 04-Feb-2025 PIPE Biotechnology
To view Cytoimmune Biologics’s complete investments history, request access »

Cytoimmune Biologics FAQs

  • When was Cytoimmune Biologics founded?

    Cytoimmune Biologics was founded in 2017.

  • Where is Cytoimmune Biologics headquartered?

    Cytoimmune Biologics is headquartered in Duarte, CA.

  • What is the size of Cytoimmune Biologics?

    Cytoimmune Biologics has 40 total employees.

  • What industry is Cytoimmune Biologics in?

    Cytoimmune Biologics’s primary industry is Drug Discovery.

  • Is Cytoimmune Biologics a private or public company?

    Cytoimmune Biologics is a Private company.

  • What is Cytoimmune Biologics’s current revenue?

    The current revenue for Cytoimmune Biologics is .

  • How much funding has Cytoimmune Biologics raised over time?

    Cytoimmune Biologics has raised $37.5M.

  • Who are Cytoimmune Biologics’s investors?

    Myeloma Investment Fund and Sofinnova Partners have invested in Cytoimmune Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process